FDA approves Hulio, sixth Humira biosimilar

The FDA has approved the sixth biosimilar to adalimumab, adalimumab-fkjp, for all eligible indications of the biologic product, according to a company press release.Hulio (adalimumab-fkjp, Mylan/Fujifilm Kyowa Kirin), a biosimilar to Humira (adalimumab, AbbVie), is a TNF inhibitor intended to treat patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis.“We are very pleased with FDA’s approval of Hulio, a biosimilar to the world’s top selling drugRead More

Share on facebook
Share on twitter
Share on linkedin